From: The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
Event
All grade-no.(%)
Grade 3–4-no.(%)
Neutrophil count decreased
21(30)
5 (7)
Platelet count decreased
23 (33)
Anemia
12 (17)
2 (2)
Alopecia
/
Diarrhea
1 (1)
Nausea
8 (12)
Vomiting